Needham & Company Starts Cantel Medical (CMN) at Hold

August 24, 2016 6:19 AM EDT
Get Alerts CMN Hot Sheet
Price: $81.14 +0.77%

Rating Summary:
    3 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade CMN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Needham & Company initiates coverage on Cantel Medical (NYSE: CMN) with a Hold rating.

Analyst Mike Matson commented,"CMN has become a leader in the $50B infection prevention and control market through a combination of strong growth (five-year sales CAGR of 16% and EPS CAGR of 17%) and savvy M&A deals (28 since 2000). CMN’s revenue growth is being driven by Endoscopy, but we think Endoscopy could slow in FY17 as its laps a competitor's recall and faces difficult comps. We expect acquisitions to provide CMN with additional growth and upside to consensus. But while we think consensus estimates are conservative, we think CMN’s premium valuation already discounts potential upside, and we initiate coverage at Hold."

For an analyst ratings summary and ratings history on Cantel Medical click here. For more ratings news on Cantel Medical click here.

Shares of Cantel Medical closed at $73.28 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Needham & Company

Add Your Comment